ES2316791T3 - Forma de dosificacion controlada por difusion y metodo de fabricacion inclusive impresion tridimensional. - Google Patents
Forma de dosificacion controlada por difusion y metodo de fabricacion inclusive impresion tridimensional. Download PDFInfo
- Publication number
- ES2316791T3 ES2316791T3 ES03747680T ES03747680T ES2316791T3 ES 2316791 T3 ES2316791 T3 ES 2316791T3 ES 03747680 T ES03747680 T ES 03747680T ES 03747680 T ES03747680 T ES 03747680T ES 2316791 T3 ES2316791 T3 ES 2316791T3
- Authority
- ES
- Spain
- Prior art keywords
- release
- dosage form
- polymer
- outer shell
- api
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002552 dosage form Substances 0.000 title claims abstract description 228
- 238000009792 diffusion process Methods 0.000 title claims abstract description 56
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 54
- 238000010146 3D printing Methods 0.000 title claims abstract description 29
- 229920000642 polymer Polymers 0.000 claims abstract description 206
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 197
- 239000002245 particle Substances 0.000 claims abstract description 85
- 238000000034 method Methods 0.000 claims abstract description 79
- 239000000203 mixture Substances 0.000 claims abstract description 65
- 239000000843 powder Substances 0.000 claims abstract description 51
- 239000000872 buffer Substances 0.000 claims abstract description 44
- 239000007788 liquid Substances 0.000 claims description 171
- 239000011230 binding agent Substances 0.000 claims description 104
- 239000000428 dust Substances 0.000 claims description 69
- 230000000903 blocking effect Effects 0.000 claims description 65
- 239000004014 plasticizer Substances 0.000 claims description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 60
- 239000000126 substance Substances 0.000 claims description 45
- 239000012530 fluid Substances 0.000 claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 31
- 230000033228 biological regulation Effects 0.000 claims description 30
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 29
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 28
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 28
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 25
- 239000011118 polyvinyl acetate Substances 0.000 claims description 24
- 230000007547 defect Effects 0.000 claims description 23
- 238000000338 in vitro Methods 0.000 claims description 19
- 239000007864 aqueous solution Substances 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 18
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 17
- 230000009477 glass transition Effects 0.000 claims description 17
- 238000001727 in vivo Methods 0.000 claims description 16
- 230000001105 regulatory effect Effects 0.000 claims description 16
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 claims description 15
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 13
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 claims description 13
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 210000001124 body fluid Anatomy 0.000 claims description 10
- 239000010839 body fluid Substances 0.000 claims description 10
- 238000007639 printing Methods 0.000 claims description 10
- 238000013270 controlled release Methods 0.000 claims description 9
- 230000007704 transition Effects 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 230000009471 action Effects 0.000 claims description 8
- 238000007906 compression Methods 0.000 claims description 8
- 230000006835 compression Effects 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical class CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 7
- 239000011521 glass Substances 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical class CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical class CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 6
- 239000001069 triethyl citrate Substances 0.000 claims description 6
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 6
- 235000013769 triethyl citrate Nutrition 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 229960003908 pseudoephedrine Drugs 0.000 claims description 4
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical class CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims description 3
- 241000416162 Astragalus gummifer Species 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 229920001615 Tragacanth Polymers 0.000 claims description 3
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims description 3
- 229960003556 aminophylline Drugs 0.000 claims description 3
- 229960001948 caffeine Drugs 0.000 claims description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000001087 glyceryl triacetate Chemical class 0.000 claims description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 229920000591 gum Polymers 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- MMMNTDFSPSQXJP-UHFFFAOYSA-N orphenadrine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 MMMNTDFSPSQXJP-UHFFFAOYSA-N 0.000 claims description 3
- 229960001687 orphenadrine citrate Drugs 0.000 claims description 3
- 235000010487 tragacanth Nutrition 0.000 claims description 3
- 239000000196 tragacanth Substances 0.000 claims description 3
- 229940116362 tragacanth Drugs 0.000 claims description 3
- 229960002622 triacetin Drugs 0.000 claims description 3
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical class CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- FXNSRODXMVUCNJ-ODZAUARKSA-N (z)-but-2-enedioic acid;hydrochloride Chemical compound Cl.OC(=O)\C=C/C(O)=O FXNSRODXMVUCNJ-ODZAUARKSA-N 0.000 claims description 2
- 240000008886 Ceratonia siliqua Species 0.000 claims description 2
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims description 2
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 238000000151 deposition Methods 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- 229960001190 pheniramine Drugs 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000011800 void material Substances 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 3
- -1 ethyl cellulose acetates Chemical class 0.000 claims 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 239000002253 acid Chemical class 0.000 claims 2
- 230000036760 body temperature Effects 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229960000725 brompheniramine Drugs 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims 2
- 229960002237 metoprolol Drugs 0.000 claims 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 2
- 235000010413 sodium alginate Nutrition 0.000 claims 2
- 239000000661 sodium alginate Substances 0.000 claims 2
- 229940005550 sodium alginate Drugs 0.000 claims 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 2
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 229920000161 Locust bean gum Polymers 0.000 claims 1
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 claims 1
- 235000010420 locust bean gum Nutrition 0.000 claims 1
- 239000000711 locust bean gum Substances 0.000 claims 1
- 229960002900 methylcellulose Drugs 0.000 claims 1
- RNTIBYGPJVJCCJ-UHFFFAOYSA-N n,n-dimethylmethanamine;ethyl 2-methylprop-2-enoate Chemical compound CN(C)C.CCOC(=O)C(C)=C RNTIBYGPJVJCCJ-UHFFFAOYSA-N 0.000 claims 1
- 229920003023 plastic Polymers 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 229940068984 polyvinyl alcohol Drugs 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 239000011162 core material Substances 0.000 description 74
- 239000010410 layer Substances 0.000 description 42
- 238000009472 formulation Methods 0.000 description 41
- 238000012360 testing method Methods 0.000 description 35
- 239000000463 material Substances 0.000 description 25
- 230000008569 process Effects 0.000 description 24
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 23
- 238000004090 dissolution Methods 0.000 description 21
- 230000004888 barrier function Effects 0.000 description 14
- 230000008595 infiltration Effects 0.000 description 12
- 238000001764 infiltration Methods 0.000 description 12
- 238000013461 design Methods 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 239000012738 dissolution medium Substances 0.000 description 7
- 230000004520 agglutination Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000010276 construction Methods 0.000 description 5
- 238000007922 dissolution test Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000001079 digestive effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000007711 solidification Methods 0.000 description 3
- 230000008023 solidification Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- 230000004523 agglutinating effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010410 dusting Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- HEYSRYRYZNGDRS-ODZAUARKSA-N (z)-but-2-enedioic acid;hydrobromide Chemical compound Br.OC(=O)\C=C/C(O)=O HEYSRYRYZNGDRS-ODZAUARKSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 231100000987 absorbed dose Toxicity 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000000203 droplet dispensing Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009415 formwork Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940089453 sudafed Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000152 swallowing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
- B29C64/10—Processes of additive manufacturing
- B29C64/141—Processes of additive manufacturing using only solid materials
- B29C64/153—Processes of additive manufacturing using only solid materials using layers of powder being selectively joined, e.g. by selective laser sintering or melting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Mechanical Engineering (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37844902P | 2002-05-06 | 2002-05-06 | |
| US378449P | 2002-05-06 | ||
| US42509402P | 2002-11-08 | 2002-11-08 | |
| US425094P | 2002-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2316791T3 true ES2316791T3 (es) | 2009-04-16 |
Family
ID=29406838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03747680T Expired - Lifetime ES2316791T3 (es) | 2002-05-06 | 2003-05-06 | Forma de dosificacion controlada por difusion y metodo de fabricacion inclusive impresion tridimensional. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8088415B2 (enExample) |
| EP (1) | EP1503741B1 (enExample) |
| JP (1) | JP5041663B2 (enExample) |
| AT (1) | ATE407665T1 (enExample) |
| AU (1) | AU2003232078A1 (enExample) |
| CA (1) | CA2483028C (enExample) |
| DE (1) | DE60323482D1 (enExample) |
| ES (1) | ES2316791T3 (enExample) |
| WO (1) | WO2003092633A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113827478A (zh) * | 2012-10-04 | 2021-12-24 | 罗伯特·W·亚当斯 | 制备控制释放医疗植入物产品的方法 |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60323482D1 (de) | 2002-05-06 | 2008-10-23 | Massachusetts Inst Technology | Diffusionskontrollierte arzneiform sowie herstellungsmethode mittels dreidimensionalem drucken |
| EP2184058B1 (en) * | 2003-09-26 | 2012-02-08 | ALZA Corporation | Drug coating providing high drug loading and methods for providing the same |
| TWI547431B (zh) * | 2004-06-09 | 2016-09-01 | 史密斯克萊美占公司 | 生產藥物之裝置及方法 |
| US20060002594A1 (en) * | 2004-06-09 | 2006-01-05 | Clarke Allan J | Method for producing a pharmaceutical product |
| US8101244B2 (en) * | 2004-06-09 | 2012-01-24 | Smithkline Beecham Corporation | Apparatus and method for producing or processing a product or sample |
| JPWO2006004069A1 (ja) * | 2004-07-01 | 2008-04-24 | 日本碍子株式会社 | 微小カプセルおよびその製造方法 |
| WO2008110337A2 (en) * | 2007-03-09 | 2008-09-18 | Synthon B.V. | Pharmaceutical composition of quetiapine fumarate |
| EP2227226B1 (en) * | 2007-12-21 | 2016-10-26 | Johnson & Johnson Consumer Inc. | Manufacture of a tablet |
| CN101716162B (zh) * | 2009-11-26 | 2012-11-14 | 扬州中宝制药有限公司 | 一种氨茶碱缓释胶囊及其制备方法 |
| US8251837B2 (en) * | 2010-08-11 | 2012-08-28 | Nike, Inc. | Floating golf ball |
| EP2651399A2 (en) | 2010-12-13 | 2013-10-23 | Purdue Pharma LP | Controlled release dosage forms |
| US9381154B2 (en) * | 2011-06-09 | 2016-07-05 | Xerox Corporation | Direct inkjet fabrication of drug delivery devices |
| US8888480B2 (en) | 2012-09-05 | 2014-11-18 | Aprecia Pharmaceuticals Company | Three-dimensional printing system and equipment assembly |
| KR101697105B1 (ko) | 2012-09-05 | 2017-01-17 | 아프레시아 파마슈티칼스 컴퍼니 | 3차원 인쇄 시스템 및 장비 어셈블리 |
| HK1216513A1 (zh) | 2013-03-15 | 2016-11-18 | 阿普雷奇亚制药有限责任公司 | 包含左乙拉西坦的快速分散劑型 |
| US9339489B2 (en) | 2013-03-15 | 2016-05-17 | Aprecia Pharmaceuticals Company | Rapid disperse dosage form containing levetiracetam |
| JP6233996B2 (ja) | 2013-08-16 | 2017-11-22 | ザ エクスワン カンパニー | ３次元印刷される金属鋳造用鋳型及び同鋳型の製造方法 |
| US20160243621A1 (en) | 2013-10-17 | 2016-08-25 | The Exone Company | Three-Dimensional Printed Hot Isostatic Pressing Containers and Processes for Making Same |
| EP2875933B1 (de) * | 2013-11-25 | 2019-04-03 | MTU Aero Engines GmbH | Dokumentation generativer Herstellungsverfahren |
| MX2016007786A (es) | 2013-12-16 | 2017-03-03 | Massachusetts Inst Technology | Formulaciones de sal de micronutrientes fortificadas. |
| EP3763383A1 (en) | 2013-12-16 | 2021-01-13 | Massachusetts Institute Of Technology | Micromolded or 3-d printed pulsatile release vaccine formulations |
| ES2745763T3 (es) | 2013-12-23 | 2020-03-03 | The Exone Co | Métodos y sistemas para la impresión en tres dimensiones utilizando múltiples fluidos aglutinantes |
| US11001048B2 (en) | 2013-12-23 | 2021-05-11 | The Exone Company | Method of three-dimensional printing using a multi-component build powder |
| IL232696B (en) | 2014-05-19 | 2018-08-30 | Technion Res & Dev Foundation | Compound and method for detecting molecules of interest |
| US20170120329A1 (en) | 2014-05-29 | 2017-05-04 | The Exone Company | Process for Making Nickel-Based Superalloy Articles by Three-Dimensional Printing |
| WO2016011098A2 (en) | 2014-07-17 | 2016-01-21 | The Exone Company | Methods and apparatuses for curing three-dimensional printed articles |
| EP3191084B2 (en) * | 2014-09-08 | 2022-08-31 | University of Central Lancashire | Solid dosage form production |
| US9844930B2 (en) | 2014-11-05 | 2017-12-19 | Xerox Corporation | 3D printing of digestible shells for medicaments |
| EP3227109B1 (en) | 2014-12-03 | 2020-08-19 | The Exone Company | Process for making densified carbon articles by three dimensional printing |
| CN106236715B (zh) * | 2015-06-03 | 2021-05-07 | 南京三迭纪医药科技有限公司 | 药品剂型及其使用 |
| EP3302442B1 (en) | 2015-06-03 | 2024-10-16 | Triastek, Inc. | Dosage forms and use thereof |
| WO2017010938A1 (en) * | 2015-07-16 | 2017-01-19 | National University Of Singapore | Printing drug tablets with fully customizable release profiles for personalized medicine |
| CN116423825A (zh) | 2015-08-21 | 2023-07-14 | 阿普雷奇亚制药有限责任公司 | 三维打印系统和设备组件 |
| GB201519128D0 (en) * | 2015-10-29 | 2015-12-16 | Univ Central Lancashire | Solid forms and methods of preparing the same |
| EP3981392A1 (en) | 2016-05-05 | 2022-04-13 | Triastek, Inc. | Controlled release dosage form |
| US12303603B2 (en) * | 2016-06-20 | 2025-05-20 | Sciperio, Inc | Real-time compounding 3D printer |
| US10765658B2 (en) | 2016-06-22 | 2020-09-08 | Mastix LLC | Oral compositions delivering therapeutically effective amounts of cannabinoids |
| GB201612853D0 (en) | 2016-07-25 | 2016-09-07 | Univ Central Lancashire | Solid dosage form production |
| EP3321002A1 (en) * | 2016-11-15 | 2018-05-16 | Höganäs AB | Feedstock for an additive manufacturing method, additive manufacturing method using the same, and article obtained therefrom |
| DE102017200773A1 (de) | 2017-01-18 | 2018-07-19 | Eos Gmbh Electro Optical Systems | Verfahren zum Nachbehandeln und Nachbehandlungssytem |
| US12102721B2 (en) * | 2017-01-26 | 2024-10-01 | Triastek, Inc. | Dosage forms of controlled release at specific gastrointestinal sites |
| US10369557B2 (en) | 2017-04-12 | 2019-08-06 | International Business Machines Corporation | Three-dimensional printed objects for chemical reaction control |
| US20210213678A1 (en) * | 2017-04-28 | 2021-07-15 | Hewlett-Packard Development Company, L.P. | Producing diffusion-controlled release devices |
| WO2019025869A1 (en) * | 2017-07-31 | 2019-02-07 | Teva Pharmaceutical Industries Limited | GALENIC FORMS WITH CONTROLLED RELEASE MANUFACTURED IN ADDITIVE MANNER |
| US11642841B2 (en) | 2017-10-13 | 2023-05-09 | Ut-Battelle, Llc | Indirect additive manufacturing process |
| US10350822B1 (en) | 2018-01-09 | 2019-07-16 | Triastek Inc. | Dosage forms with desired release profiles and methods of designing and making thereof |
| CN116270513A (zh) | 2018-01-09 | 2023-06-23 | 南京三迭纪医药科技有限公司 | 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型 |
| WO2019183470A2 (en) | 2018-03-22 | 2019-09-26 | Incarda Therapeutics, Inc. | A novel method to slow ventricular rate |
| DE102018107585B3 (de) * | 2018-03-29 | 2019-03-28 | Universität Rostock | Vorrichtung zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen mit Wirkstoffdepots, sowie Verfahren zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen |
| WO2019199328A1 (en) * | 2018-04-13 | 2019-10-17 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| CN108939162B (zh) * | 2018-07-10 | 2021-11-19 | 上海理工大学 | 一种介孔生物玻璃/海藻酸钠-海藻酸钠分层骨组织工程支架的制备方法 |
| GB201813186D0 (en) | 2018-08-13 | 2018-09-26 | Univ Central Lancashire | Solid dosage from production |
| AU2019337800A1 (en) * | 2018-09-14 | 2021-05-13 | Merck Patent Gmbh | Process for the preparation of a coated solid pharmaceutical dosage form |
| US11278501B2 (en) | 2018-10-15 | 2022-03-22 | Aprecia Pharmaceuticals LLC | Method and system for forming a dosage form within a packaging |
| US11254617B2 (en) | 2019-01-09 | 2022-02-22 | Ut-Battelle, Llc | Indirect additive manufacturing process using amine-containing adhesive polymers |
| US12103229B2 (en) * | 2019-03-15 | 2024-10-01 | Ricoh Company, Ltd. | Jettable temporary binders to create removable support materials |
| US11724486B2 (en) | 2019-07-09 | 2023-08-15 | Kyndryl, Inc. | Printing customized medication based on current user data and medical records of the user |
| AU2020329531A1 (en) * | 2019-08-14 | 2022-03-31 | Merck Patent Gmbh | Method for additive manufacture of a product, manufacturing device and solid pharmaceutical dosage form |
| GB201913972D0 (en) | 2019-09-27 | 2019-11-13 | Univ Ulster | Pharmaceutical Delivery Device and method of manufacture |
| ES2828509B2 (es) | 2019-11-26 | 2022-03-09 | Fund Idonial | Composicion para la impresion 3d de farmacos semisolidos |
| EP3871859A1 (en) * | 2020-02-26 | 2021-09-01 | Hewlett-Packard Development Company, L.P. | Three-dimensional printing |
| JP7624750B2 (ja) * | 2020-03-02 | 2025-01-31 | クラフト ヘルス プライベート リミテッド | 持続的薬物放出のための経口剤形 |
| CN115835856A (zh) | 2020-05-13 | 2023-03-21 | 麻省理工学院 | 聚合物微装置的组合物以及其在癌症免疫疗法中的用途 |
| MX2022016117A (es) | 2020-06-26 | 2023-04-05 | Aprecia Pharmaceuticals LLC | Tabletas rapidamente orodispersables que tienen una cavidad interior. |
| US20230390193A1 (en) | 2020-10-30 | 2023-12-07 | Triastek, Inc. | Gastroretentive pharmaceutical dosage form |
| US12251208B2 (en) | 2020-11-30 | 2025-03-18 | International Business Machines Corporation | Time controlled medication |
| KR102723494B1 (ko) * | 2020-12-24 | 2024-10-31 | 동아제약 주식회사 | 적층 방식으로 제조된 방출 조절용 약제학적 조성물 |
| CN112940690B (zh) * | 2021-02-05 | 2021-11-02 | 中国科学院苏州纳米技术与纳米仿生研究所南昌研究院 | 一种具有豆荚结构的相变储能材料及其制备方法与应用 |
| WO2024108084A1 (en) * | 2022-11-18 | 2024-05-23 | Aprecia Pharmaceuticals LLC | Functionally-dividable orodispersive dosage form |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US948297A (en) * | 1909-07-24 | 1910-02-01 | John A Stone | Corn-husker. |
| US986148A (en) * | 1910-05-09 | 1911-03-07 | Hoechst Ag | Derivative of oxyarylarsinic acids and process of making same. |
| ZA822995B (en) * | 1981-05-21 | 1983-12-28 | Wyeth John & Brother Ltd | Slow release pharmaceutical composition |
| DE3586600T2 (de) * | 1984-02-10 | 1993-02-18 | Benzon Pharma As | Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend. |
| US4810502A (en) * | 1987-02-27 | 1989-03-07 | Alza Corporation | Pseudoephedrine brompheniramine therapy |
| US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5204055A (en) * | 1989-12-08 | 1993-04-20 | Massachusetts Institute Of Technology | Three-dimensional printing techniques |
| NZ286242A (en) * | 1991-03-26 | 1997-11-24 | Csl Ltd | Use of veterinary implant as a single dose vaccination system: rupturable polymer film coating around core of active agent and water soluble excipient |
| US5775402A (en) * | 1995-10-31 | 1998-07-07 | Massachusetts Institute Of Technology | Enhancement of thermal properties of tooling made by solid free form fabrication techniques |
| US5490882A (en) * | 1992-11-30 | 1996-02-13 | Massachusetts Institute Of Technology | Process for removing loose powder particles from interior passages of a body |
| US5490962A (en) * | 1993-10-18 | 1996-02-13 | Massachusetts Institute Of Technology | Preparation of medical devices by solid free-form fabrication methods |
| US6280771B1 (en) * | 1997-02-20 | 2001-08-28 | Therics, Inc. | Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof |
| US6238704B1 (en) * | 1996-09-13 | 2001-05-29 | Shionogi & Co., Ltd. | Sustained-release preparation utilizing thermal change and process for the production thereof |
| JP4563516B2 (ja) * | 1997-02-20 | 2010-10-13 | マサチューセッツ インスティテュート オブ テクノロジー | 迅速分散性を示す投与剤形、その使用法並びにその製造方法 |
| US6213168B1 (en) * | 1997-03-31 | 2001-04-10 | Therics, Inc. | Apparatus and method for dispensing of powders |
| WO1998043762A2 (en) * | 1997-03-31 | 1998-10-08 | Therics, Inc. | Method for dispensing of powders |
| US6547994B1 (en) * | 1998-11-13 | 2003-04-15 | Therics, Inc. | Rapid prototyping and manufacturing process |
| US6485746B1 (en) * | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
| DE19961897A1 (de) * | 1999-12-20 | 2001-06-28 | Basf Ag | Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen |
| DE10015479A1 (de) * | 2000-03-29 | 2001-10-11 | Basf Ag | Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität |
| ES2257412T3 (es) * | 2000-05-18 | 2006-08-01 | Therics, Inc. | Encapsulacion de un nucleo toxico en una region no toxica en una forma de dosificacion oral. |
| US20020084290A1 (en) * | 2000-11-10 | 2002-07-04 | Therics, Inc. | Method and apparatus for dispensing small volume of liquid, such as with a weting-resistant nozzle |
| DE60323482D1 (de) | 2002-05-06 | 2008-10-23 | Massachusetts Inst Technology | Diffusionskontrollierte arzneiform sowie herstellungsmethode mittels dreidimensionalem drucken |
| US20050015728A1 (en) * | 2003-07-17 | 2005-01-20 | International Business Machines Corporation | Method, system, and program product for customizing a user interface |
-
2003
- 2003-05-06 DE DE60323482T patent/DE60323482D1/de not_active Expired - Lifetime
- 2003-05-06 CA CA2483028A patent/CA2483028C/en not_active Expired - Lifetime
- 2003-05-06 JP JP2004500818A patent/JP5041663B2/ja not_active Expired - Lifetime
- 2003-05-06 EP EP03747680A patent/EP1503741B1/en not_active Expired - Lifetime
- 2003-05-06 AT AT03747680T patent/ATE407665T1/de not_active IP Right Cessation
- 2003-05-06 WO PCT/US2003/014376 patent/WO2003092633A2/en not_active Ceased
- 2003-05-06 AU AU2003232078A patent/AU2003232078A1/en not_active Abandoned
- 2003-05-06 ES ES03747680T patent/ES2316791T3/es not_active Expired - Lifetime
- 2003-05-06 US US10/431,353 patent/US8088415B2/en active Active
-
2011
- 2011-11-29 US US13/306,393 patent/US8465777B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113827478A (zh) * | 2012-10-04 | 2021-12-24 | 罗伯特·W·亚当斯 | 制备控制释放医疗植入物产品的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1503741A2 (en) | 2005-02-09 |
| DE60323482D1 (de) | 2008-10-23 |
| ATE407665T1 (de) | 2008-09-15 |
| JP2005524702A (ja) | 2005-08-18 |
| WO2003092633A3 (en) | 2004-04-08 |
| EP1503741B1 (en) | 2008-09-10 |
| CA2483028C (en) | 2011-04-05 |
| WO2003092633A2 (en) | 2003-11-13 |
| JP5041663B2 (ja) | 2012-10-03 |
| US20040005360A1 (en) | 2004-01-08 |
| US8088415B2 (en) | 2012-01-03 |
| AU2003232078A1 (en) | 2003-11-17 |
| CA2483028A1 (en) | 2003-11-13 |
| US20120177696A1 (en) | 2012-07-12 |
| US8465777B2 (en) | 2013-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2316791T3 (es) | Forma de dosificacion controlada por difusion y metodo de fabricacion inclusive impresion tridimensional. | |
| US20230115025A1 (en) | Gastro-retentive drug delivery system | |
| ES2318869T3 (es) | Forma de dosificacion que presenta propiedades de dispersion rapida, metodos de uso y procedimiento para su fabricacion. | |
| Awad et al. | Solid oral dosage forms | |
| Wang et al. | Asymmetric membrane capsules for delivery of poorly water-soluble drugs by osmotic effects | |
| HRP20030082A2 (en) | Hydrogel-driven drug dosage form | |
| TW200425888A (en) | Controlled-release of an active substance into a high fat environment | |
| ES2305524T3 (es) | Sistema de aporte controlado de sustancias bioactivas. | |
| US20150202158A1 (en) | Gastro-retentive drug delivery system | |
| Sah et al. | Sublingual tablets: an overview | |
| US20250064727A1 (en) | Gastroretentive fibrous dosage form for prolonged drug delivery | |
| Maheswari et al. | Formulation and evaluation of controlled porosity osmotic tablets of lornoxicam | |
| ES2977944T3 (es) | Composiciones farmacéuticas orales con retención gástrica a base de baclofeno | |
| Lindberg et al. | Effervescent pharmaceuticals | |
| Barzegar-Jalali et al. | Design and Evaluation of Delayed-Release Osmotic Capsule of Acetaminophen: Delayed-release osmotic capsule of acetaminophen | |
| US20220304924A1 (en) | Expandable multi-excipient dosage form | |
| ES3040756T3 (en) | Hydrocortisone acetate suppository formulation for use in treating inflammatory bowel disease | |
| Tarannum et al. | Formulation Evaluation and Development of Specialized Tablets | |
| Pujara et al. | Osmotically controlled oral drug delivery systems: a novel approach | |
| Gupta et al. | Role of matrix tablet in sustained release system | |
| Parekh | Formulation Development and Evaluation of Osmotic Drug Delivery System | |
| WO2025043032A1 (en) | Fluid-absorptive gastroretentive dosage form for prolonged drug delivery | |
| Waldner et al. | Development of a dosage form for accelerated release | |
| von Orelli | Search for Technological Reasons to develop a Capsule or a Tablet Formulation | |
| Mehuys | Development of a matrix-in-cylinder system for sustained zero-order drug release |